PriceTargets.com logo

Lantern Pharma - LTRN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 222.58%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.41 As of 09/29/2023 01:00 AM ET
▼ -0.04 (-1.16%)

This chart shows the closing price for LTRN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lantern Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LTRN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LTRN

Analyst Price Target is $11.00
▲ +222.58% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Lantern Pharma in the last 3 months. The average price target is $11.00, with a high forecast of $11.00 and a low forecast of $11.00. The average price target represents a 222.58% upside from the last price of $3.41.

This chart shows the closing price for LTRN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 2 polled investment analysts is to moderate buy stock in Lantern Pharma. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2023HC WainwrightReiterated RatingNeutralLow
3/21/2023EF Hutton Acquisition Co. IReiterated RatingBuy$11.00Low
2/15/2023EF Hutton Acquisition Co. IReiterated RatingBuy$11.00Low
11/1/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$11.00Low
3/22/2022Colliers SecuritiesReiterated RatingBuyHigh
3/11/2022HC WainwrightBoost TargetBuy$34.00 ➝ $36.00Medium
11/2/2021HC WainwrightBoost TargetBuy$32.00 ➝ $34.00High
10/7/2021HC WainwrightInitiated CoverageBuy$32.00Medium
7/30/2021Colliers SecuritiesReiterated RatingBuy$29.00Medium
7/21/2021Colliers SecuritiesReiterated RatingBuy$29.00Low
8/18/2020ThinkEquityReiterated RatingBuy ➝ Market Perform$25.00High
8/18/2020Colliers SecuritiesReiterated RatingBuy ➝ Market Perform$24.00High
8/10/2020ThinkEquityInitiated CoverageBuyHigh
7/28/2020Colliers SecuritiesInitiated CoverageBuy$24.00High
(Data available from 9/30/2018 forward)

News Sentiment Rating

0.61 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2023
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
4/3/2023
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2023
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
8/31/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2023

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Lantern Pharma logo
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Read More

Today's Range

Now: $3.41
Low: $3.41
High: $3.60

50 Day Range

MA: $4.40
Low: $3.41
High: $5.00

52 Week Range

Now: $3.41
Low: $3.38
High: $6.20

Volume

11,740 shs

Average Volume

22,585 shs

Market Capitalization

$37.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Lantern Pharma?

The following Wall Street sell-side analysts have issued reports on Lantern Pharma in the last year: EF Hutton Acquisition Co. I, and HC Wainwright.
View the latest analyst ratings for LTRN.

What is the current price target for Lantern Pharma?

1 Wall Street analysts have set twelve-month price targets for Lantern Pharma in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 222.6%. EF Hutton Acquisition Co. I has the highest price target set, predicting LTRN will reach $11.00 in the next twelve months. EF Hutton Acquisition Co. I has the lowest price target set, forecasting a price of $11.00 for Lantern Pharma in the next year.
View the latest price targets for LTRN.

What is the current consensus analyst rating for Lantern Pharma?

Lantern Pharma currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for LTRN.

What other companies compete with Lantern Pharma?

Other companies that are similar to Lantern Pharma include Viracta Therapeutics, Marker Therapeutics, Coya Therapeutics, Societal CDMO and CytoMed Therapeutics. Learn More about companies similar to Lantern Pharma.

How do I contact Lantern Pharma's investor relations team?

Lantern Pharma's physical mailing address is 1920 MCKINNEY AVENUE 7TH FLOOR, DALLAS TX, 75201. The company's listed phone number is 972-277-1136 and its investor relations email address is inf[email protected]. The official website for Lantern Pharma is www.lanternpharma.com. Learn More about contacing Lantern Pharma investor relations.